Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:medical_condition
gptkb:adverse_drug_reaction |
| gptkbp:causedBy |
gptkb:haloperidol
|
| gptkbp:complication |
gptkb:arrhythmia
renal failure rhabdomyolysis |
| gptkbp:mortalityRate |
10-20% (untreated)
|
| gptkbp:onset |
hours to days after haloperidol initiation
|
| gptkbp:riskFactor |
dehydration
agitation rapid dose escalation high dose haloperidol |
| gptkbp:subspecies |
neuroleptic malignant syndrome
|
| gptkbp:symptom |
elevated creatine kinase
autonomic dysfunction hyperthermia altered mental status muscle rigidity |
| gptkbp:treatment |
gptkb:dantrolene
supportive care bromocriptine discontinuation of haloperidol |
| gptkbp:bfsParent |
gptkb:Neuroleptic_Malignant_Syndrome
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Haloperidol-induced NMS
|